Boardroom Alpha
8-K primary document
SKYE · Current Report (Form 8-K) · Filed August 14, 2026

Skye Bioscience Inc8-K exhibit

ex031-skyebioscienceincx.htm
ex031-skyebioscienceincx
Certificate of Change Pursuant to NRS 78.209 TYPE OR PRINT - USE DARK INK ONLY - DO NOT HIGHLIGHT  INSTRUCTIONS:   1. Enter the current name as on file with the Nevada Secretary of State and enter the Entity or Nevada Business Identification Number (NVID). 2. Indicate the current number of authorized shares and par value, if any, and each class or series before the change. 3. Indicate the number of authorized shares and par value, if any of each class or series after the change. 4. Indicate the change of the affected class or series of issued, if any, shares after the change in exchange for each issued share of the same class or series. 5. Indicate provisions, if any, regarding fractional shares that are affected by the change. 6. NRS required statement. 7. This section is optional. If an effective date and time is indicated the date must not be more than 90 days after the date on which the certificate is filed. 8. Must be signed by an Officer. Form will be returned if unsigned. 1. Entity Information: Name of entity as on file with the Nevada Secretary of State: Skye Bioscience, Inc.   Entity or Nevada Business Identification Number (NVID): NV20111180416   2. Current Authorized Shares: The current number of authorized shares and the par value, if any, of each class or series, if any, of shares before the change:    300,000,000 shares of common stock, par value $0.001 per share 200,000 shares of preferred stock, par value $0.001 per share   3. Authorized Shares After Change: The number of authorized shares and the par value, if any, of each class or series, if any, of shares after the change:    37,500,000 shares of common stock, par value $0.001 per share 200,000 shares of preferred stock, par value $0.001 per share   4. Issuance: The number of shares of each affected class or series, if any, to be issued after the change in exchange for each issued share of the same class or series:    One-eighth of a share of common stock will be issued in exchange for each share of common stock issued and outstanding as of the effective date.   5. Provisions: The provisions, if any, for the issuance of fractional shares, or for the payment of money or the issuance of scrip to stockholders otherwise entitled to a fraction of a share and the percentage of outstanding shares affected thereby:    Fractional shares shall be paid in cash based on the post-split adjusted Nasdaq closing price on the trading day preceding the effective date. Less than 1% of the outstanding shares are expected to be affected.   6. Provisions: The required approval of the stockholders has been obtained.   7. Effective Date and time: (Optional) Date:     08/24/2026 Time:     12:01 AM           (must not be later than 90 days after the certificate is filed)     FRANCISCO V. AGUILAR Secretary of State 401 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website:  www.nvsos.gov This form must be accompanied by appropriate fees. If necessary, additional pages may be attached to this form.  Page 1 of 2 Revised: 1/1/2019 Filed in the Office of Secretary of State State Of Nevada Business Number E0149202011-9 Filing Number 20265965640 Filed On 08/12/2026 14:10:36 PM Number of Pages 2


 
8. Signature: (Required) X Signature of Officer  Punit Dhillon Title Officer Date 08/12/2026     FRANCISCO V. AGUILAR Secretary of State 401 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website:  www.nvsos.gov This form must be accompanied by appropriate fees. If necessary, additional pages may be attached to this form.  Page 2 of 2 Revised: 1/1/2019


 
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer